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A 74-year-old woman came to the Endocrinology Poly-
clinic in April 2008 due to pain in the front part of the 
neck, an increase in body temperature to 38°C, muscle 
and joint pain, hoarseness, and general weakness that 
had been present for several days. She had not been 
treated or diagnosed for thyroid disease. At that time, 
the patient noticed a sudden, significant enlargement 
of the right lobe of the thyroid with a large tumour. 
She also felt shortness of breath, which intensified with 
physical exertion. In a medical interview, she reported 
that she had been suffering from type 2 diabetes, arterial 
hypertension, glaucoma, and degenerative changes in 
the spine. The thyroid ultrasound revealed a signifi-
cantly enlarged right lobe of the thyroid with a poly-
cyclic tumour 6 cm size, containing a large calcification 
of about 2 cm on its periphery. There were no focal 
changes in the left lobe (of the correct size).  
Fine-needle aspiration biopsy revealed a necrotic 
mass with numerous atypical cells. 
Laboratory tests revealed euthyroidism, microcytic 
anaemia (Hb — 10.9 g%), increased erythrocyte sedi-
mentation rate — 59 mm/h and leucocytosis — 12,600. 
The patient was referred urgently for thyroid surgery. 
Complete excision of the right lobe and subtotal resec-
tion of the left lobe was performed. Due to the tumour 
infiltration of the surrounding tissues, including the 
trachea, the strumectomy procedure was oncologically 
non-radical. G3 undifferentiated (anaplastic) thyroid 
carcinoma (ATC) was diagnosed with histopathology, 
with metastases to the lymph nodes in the state of 
partial necrosis. The immunohistochemical reaction 
for cytokeratin (CK) and epithelial membrane antigen 
(EMA) was positive. Extensive cellular polymorphism, 
marked nuclear atypia, numerous abnormal division 
patterns, and small lymphocyte clusters between 
neoplastic cells have been described in postoperative 
preparations. The features of squamous epithelium 
differentiation, anaplastic cell field with visible division 
figures, and with lymphocyte inflammatory infiltration 
were visible (Fig. 1, 2).
After the surgery, the patient’s dyspnoea disap-
peared. Thyroxine substitution (137–150 ug) was initi-
ated, with good hormone dose tolerance. The patient 
was referred to the Institute of Oncology in Gliwice, 
where further diagnostics of the advancement of the 
neoplastic disease was performed and specialistic treat-
ment was started. Undifferentiated thyroid cancer was 
defined as T4N1bMx in the patient. 
A month later, neck and chest computed tomogra-
phy revealed metastatic right paratracheal lymph nodes 
near the tumour bed and level II B lymph nodes suspi-
cious for metastasis in the right neck. A mass (diameter 
14 mm) was also noted in the tumour bed of the left 
lobe. On targeted biopsy the lymph nodes were positive 
for malignancy, while the specimen from the left lobe 
mass revealed the presence of colloid and dispersed 
normal thyroid cells.
Postoperative scintigraphy showed a higher tracer 
uptake in this region with no other areas of radiotracer 
uptake.
The case of this patient was presented to the Thy-
roid Tumour Group at the Institute of Oncology in 
Gliwice. Due to the non-radical surgical procedure 
(because of the infiltration of adjacent tissues, includ-
ing the trachea) and the histopathological nature of 
the tumour, it was decided to attempt treatment with 
an ablative-therapeutic dose of radioactive iodine (131J) 
in terms of possible assessment of loco-regional iodine 
uptake.
The patient received iodine-131 (98mCi) 3 times every 
6 months, after stimulation with thyrotropin alfa. In 
November 2008, she was referred for neck radiotherapy 
(5600 cGy/g over 6 weeks). Follow-up scintigraphy in 
October 2009 revealed no radiotracer uptake.
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Currently, the patient is 87 years old. A follow-up 
ultrasound of the neck area shows a volume area of 
about 0.6 mL with the features of a fibrotic stump in 
the left lobe bed. She does not report local or general 
complaints related to thyroid neoplastic disease, and 
she undergoes routine medical check-ups.
Anaplastic thyroid carcinoma is a very malignant 
type of neoplasm with poor prognosis, with mortality 
reaching 100% within a few months. 
It arises as a primary tumour from undifferentiated 
thyroid cells or following progression of well-differen-
tiated papillary or follicular carcinoma [1].
Molecular aberrations are implicated in the patho- 
genesis, with the TP53 gene mutation as the main 
underlying mechanism [2]. Patients are almost always 
euthyroid. The mean age at diagnosis is 65 years. The 
disease course is characterized by aggressive tumour 
growth and local invasion of the surrounding structures 
[3]. Histologically, the tumour is composed of highly 
anaplastic giant, polymorphic, or spindle-shaped 
cells. Necrotic changes in the tumour occur rapidly, 
with macrophage infiltrates. Distant metastasis of 
cancer is frequent, but death usually occurs as a result 
of damage to vital structures within the neck [4]. Most 
often, ATC does not produce thyroglobulin, nor does 
it accumulate radioactive iodine [5]. In the treatment 
of this type of cancer (ATC), thyroid resection, possibly 
complete, and external teleradiotherapy are recom-
mended. In recent years, trials of pharmacotherapy 
have been reported. However, chemotherapy does 
not show the expected positive therapeutic effects [6, 
7]. Ferrari et al. [8] emphasize the important role of 
molecular tests in selecting the form of therapy in each 
patient with ATC. Despite many studies on this cancer, 
the current treatment strategy for anaplastic thyroid 
cancer is still insufficient for significant extension of the 
patient’s life [9]. Based on the case of an elderly woman 
with 13 years of ATC (still alive, without evidence of 
an active neoplastic disease), a thesis can be made 
that a very individually selected form of therapy for 
this cancer is necessary. In this case, the strumectomy 
(non-radical), as well as external radiotherapy and 
131-J therapy gave a good effect in the form of very 
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Figure 2. Anaplastic thyroid cancer. Anaplastic cell fields with 
lymphocyte inflammatory infiltration, features of squamous cell 
differentiation. Haematoxylin and eosin staining (×200)
Figure 1. Anaplastic thyroid cancer. Fields of anaplastic cells, 
division figures visible. Haematoxylin and eosin staining (×100)
